A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
Public ClinicalTrials.gov record NCT01334918. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT) stress myocardial perfusion imaging (MPI) with regadenoson in order to detect the presence or absence of reversible defects.
Study identification
- NCT ID
- NCT01334918
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 124 participants
Conditions and interventions
Conditions
Interventions
- regadenoson Drug
- technetium Tc99m sestamibi /technetium Tc99m tetrafosmin Radiation
- Contrast Radiation
- Single Photon Emission Computed Tomography Procedure
- Multidetector Computed Tomography Procedure
Drug · Radiation · Procedure
Eligibility (public fields only)
- Age range
- 45 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 26, 2011 (Actual)
- Primary completion
- Jul 2, 2012 (Actual)
- Completion
- Jul 2, 2012 (Actual)
- Last update posted
- Dec 4, 2024
2011 – 2012
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sutter Roseville Medical Center | Roseville | California | 95661 | — |
| Harbor UCLA Medical Center | Torrance | California | 90502 | — |
| Cardiovascular Research Center of South Florida | Miami | Florida | 33173 | — |
| Baptist Hospital of Miami | Miami | Florida | 33176 | — |
| Midwest Cardiology Associates, P.C. | Overland Park | Kansas | 66029 | — |
| Maine Research Associates | Auburn | Maine | 04210 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Berkshire Medical Center | Pittsfield | Massachusetts | 01201 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01334918, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 4, 2024 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01334918 live on ClinicalTrials.gov.